Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis

Journal of Cellular Physiology

Volumn 226, Issue 12, 2011, Pages 3219-3224

  Yazbeck, Roger ^a,b,c   Howarth, Gordon S ^a,b,d   Butler, Ross N ^c   Geier, Mark S ^d   Abbott, Catherine A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SUCRASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMICAL COMPOSITION; COLITIS; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOLOGY; INTESTINE VILLUS; JEJUNUM; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE;

ANIMALS; BIOLOGICAL MARKERS; COLITIS; DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; ILEUM; INTESTINE, SMALL; ISOLEUCINE; JEJUNUM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROVILLI; NEUTROPHIL INFILTRATION; PEROXIDASE; SUCRASE; THIAZOLES; TIME FACTORS;

MUS; THIA;

EID: 80053153428     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22682     Document Type: Article

References (50)

1. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. 2000. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267: 6140-6150.
2. Ahren B. 2009. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-Diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 23: 487-498.
3. Anthony A, Pounder RE, Dhillon AP, Wakefield AJ. 1997. Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 41: 763-770.
4. Araki Y, Andoh A, Tsujikawa T, Fujiyama Y, Bamba T. 2001. Alterations in intestinal microflora, faecal bile acids and short chain fatty acids in dextran sulphate sodium-induced experimental acute colitis in rats. Eur J Gastroenterol Hepatol 13: 107-112.
5. Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, Faust J, Fuchs P, Sens B, Neubert K, Tager M, Ansorge S. 2006. Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13)-A novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 6: 1925-1934.
6. Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M. 2008. Inflammatory bowel diseases: Multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci 13: 3699-3713.
7. Beaulieu JF, Nichols B, Quaroni A. 1989. Posttranslational regulation of sucrase-isomaltase expression in intestinal crypt and villus cells. J Biol Chem 264: 20000-20011.
8. Beyer AJ, Smalley DM, Shyr YM, Wood JG, Cheung LY. 1998. PAF and CD18 mediate neutrophil infiltration in upper gastrointestinal tract during intra-abdominal sepsis. Am J Physiol 275: G467-G472.
9. Chen T, Smyth D, Abbott CA. 2004. Cd26. J Biol Regul Homeost Agents 18: 47-54.
10. Clarke JM, Pelton NC, Bajka BH, Howarth GS, Read LC, Butler RN. 2006. Use of the 13C-sucrose breath test to assess chemotherapy-induced small intestinal mucositis in the rat. Cancer Biol Ther 5: 34-38.
11. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB. 2003. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100: 6825-6830.
12. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
13. Dahlqvist A. 1968. Assay of intestinal disaccharidases. Anal Biochem 22: 99-107.
14. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652.
15. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. 2000. Characterisation of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion 62: 240-248.
16. Erickson RH, Suzuki Y, Sedlmayer A, Kim YS. 1992. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. J Biol Chem 267: 21623-21629.
17. Frerker N, Wagner L, Wolf R, Heiser U, Hoffmann T, Rahfeld JU, Schade J, Karl T, Naim HY, Alfalah M, Demuth HU, von Horsten S. 2007. Neuropeptide Y (NPY) cleaving enzymes: Structural and functional homologues of dipeptidyl peptidase 4. Peptides 28: 257-268.
18. Fura A, Khanna A, Vyas V, Koplowitz B, Chang SY, Caporuscio C, Boulton DW, Christopher LJ, Chadwick KD, Hamann LG, Humphreys WG, Kirby M. 2009. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 37: 1164-1171.
19. Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G, Caprilli R. 1999. Dextran sulfate sodium (DSS) colitis in rats: Clinical, structural, and ultrastructural aspects. Dig Dis Sci 44: 1458-1475.
20. Geier MS, Tenikoff D, Yazbeck R, McCaughan GW, Abbott CA, Howarth GS. 2005. Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol 204: 687-692.
21. Geier MS, Butler RN, Giffard PM, Howarth GS. 2007a. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol 114: 267-274.
22. Geier MS, Butler RN, Giffard PM, Howarth GS. 2007b. Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats. Dis Colon Rectum 50: 1061-1069.
23. Geier MS, Smith CL, Butler RN, Howarth GS. 2009. Small-intestinal manifestations of dextran sulfate sodium consumption in rats and assessment of the effects of Lactobacillus fermentum BR11. Dig Dis Sci 54: 1222-1228.
24. Greischel A, Binder R, Baierl J. 2010. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: Results from high resolution autoradiography in rats. Drug Metab Dispos 38: 1443-1448.
25. Heinecke JW, Li W, Francis GA, Goldstein JA. 1993. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest 91: 2866-2872.
26. Hoffmann T, Demuth HU. 2002. Therapeutic strategies exploiting DP IV inhibition-target disease: Type 2 diabetes. Ectopeptidases: CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology. pp 259-278.
27. Hunter LC, O'Hare A, Herron WJ, Fisher LA, Jones GE. 2003. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol 45: 121-128.
28. Jeppesen PB. 2003. Clinical significance of GLP-2 in short-bowel syndrome. J Nutr 133: 3721-3724.
29. Kawada M, Arihiro A, Mizoguchi E. 2007. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 13: 5581-5593.
30. Lambeir AM, Scharpe S, De Meester I. 2008. DPP4 inhibitors for diabetes-What next? Biochem Pharmacol 76: 1637-1643.
31. Levin RJ. 1994. Digestion and absorption of carbohydrates-From molecules and membranes to humans. Am J Clin Nutr 59: 690S-698S.
32. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. 2000. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97: 6874-6879.
33. McIntosh CH. 2008. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front Biosci 13: 1753-1773.
34. Miura S, Song IS, Morita A, Erickson RH, Kim YS. 1983. Distribution and biosynthesis of aminopeptidase N and dipeptidyl aminopeptidase IV in rat small intestine. Biochim Biophys Acta 761: 66-75.
35. Morita A, Chung YC, Freeman HJ, Erickson RH, Sleisenger MH, Kim YS. 1983. Intestinal assimilation of a proline-containing tetrapeptide. Role of a brush border membrane postproline dipeptidyl aminopeptidase IV. J Clin Invest 72: 610-616.
36. Ni J, Chen SF, Hollander D. 1996. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39: 234-241.
37. Ohtsuka Y, Sanderson IR. 2003. Dextran sulfate sodium-induced inflammation is enhanced by intestinal epithelial cell chemokine expression in mice. Pediatr Res 53: 143-147.
38. Ohtsuka Y, Lee J, Stamm DS, Sanderson IR. 2001. MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine. Gut 49: 526-533.
39. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.
40. Pitman MR, Sulda ML, Kuss B, Abbott CA. 2009. Dipeptidyl peptidase 8 and 9-Guilty by association? Front Biosci 14: 3619-3633.
41. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. 2003. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750.
42. Puschel G, Mentlein R, Heymann E. 1982. Isolation and characterization of dipeptidyl peptidase IV from human placenta. Eur J Biochem 126: 359-365.
43. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE. 1995. Free radicals and phagocytic cells. FASEB J 9: 200-209.
44. Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS. 2008. Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr Cancer 60: 757-767.
45. Stevceva L, Pavli P, Husband AJ, Doe WF. 2001. The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin Pathol 1: 3.
46. Tiruppathi C, Miyamoto Y, Ganapathy V, Leibach FH. 1993. Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 265: G81-G89.
47. Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. 2008. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 13: 6850-6858.
48. Yazbeck R, Howarth GS, Abbott CA. 2009. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 30: 600-607.
49. Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Horsten S, Holst JJ, Abbott CA. 2010. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 16: 1340-1351.
50. Yu DM, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman MR, Abbott CA, McCaughan GW, Gorrell MD. 2009. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 57: 1025-1040.